When was InNeuroCo founded?

InNeuroCo was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is InNeuroCo located?

InNeuroCo is headquartered in Sunrise, United States.

How many employees does InNeuroCo have?

As of Apr 30, 2026, the latest employee count at InNeuroCo is 20.

Is InNeuroCo a funded company?

InNeuroCo is a funded company, having raised a total of $1.51M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 02, 2015.

When was the latest funding round of InNeuroCo?

InNeuroCo's latest funding was a $***** Conventional Debt round on Jun 14, 2017, with participation from 0 investor.

Where does InNeuroCo rank among its competitors?

InNeuroCo ranks 7th amongst 28 active competitors, of which 9 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Robeauté, which secured $28M in Jan, 2025.

InNeuroCo - 2026 Company Profile, Team, Funding & Competitors

Q: Who are the top competitors of InNeuroCo?

InNeuroCo's top competitors include Q’Apel Medical, Huake Precision (Beijing) Medical Technology and Brain Navi Biotechnology. Among them, Robeauté secured the most recent funding round in January, 2025.

InNeuroCo is an acquired company based in Sunrise (United States), founded in 2014 by Daniel Sablyak and Marc Litzenberg. It operates as an Intermediate catheters and super distal access device for neurovascular surgery. InNeuroCo has raised $1.51M in funding. The company has 28 active competitors, including 9 funded and 6 that have exited. Its top competitors include companies like Q’Apel Medical, Huake Precision (Beijing) Medical Technology and Brain Navi Biotechnology.

Company Details

InNeuroCo is a developer of devices for neurovascular surgeries. The company's Super Distal Access (SDA) is FDA 510(k) cleared (K161262) and it is indicated for the introduction of interventional devices into the peripheral and neuro vasculature. The company's Long Sheath also received FDA 510(k) clearance (K152876) and is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature. The company has partnered with Codman Neuro for the distribution of its intermediate catheter range.

Website: inneuroco.com
Email ID: *****@inneuroco.com

Key Metrics

Founded Year

2014

Location

Sunrise, United States

Stage

Acquired

Total Funding

$1.51M in 3 rounds

Latest Funding Round

Conventional Debt, Jun 14, 2017, $*****

Ranked

7^th among 28 active competitors

Employee Count

20 as on Apr 30, 2026

Similar Companies

Q’Apel Medical & 37 more

Exit Details

Acquired by Integer (Oct 25, 2023)

View InNeuroCo's full profile

InNeuroCo is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
INNEUROCO, INC CIN: 320453109 , United States, Active		-	108 (As on Dec 31, 2023)	-

InNeuroCo got acquired by Integer on Oct 25, 2023.

Click here to take a look at InNeuroCo's acquisition in detail

InNeuroCo has raised a total funding of $1.51M over 3 rounds. Its first funding round was on Jan 02, 2015.

Here is the list of recent funding rounds of InNeuroCo:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 14, 2017	7248955	Conventional Debt	9589410	9840386	5863868	6794859
Jun 25, 2015	3557090	Seed	9195877	7938977	4308012	6040439
Jan 02, 2015	3696549	Seed	8861409	8262349	7215876	8752181

Access funding benchmarks and valuations. Sign up today!

View details of InNeuroCo's funding rounds and investors

The founders of InNeuroCo are Daniel Sablyak and Marc Litzenberg. Marc Litzenberg is the CEO of InNeuroCo.

Here are the details of InNeuroCo's key team members:

Daniel Sablyak: Co-Founder & CTO of InNeuroCo.
Marc Litzenberg: Founder & CEO of InNeuroCo.

View details of InNeuroCo's Founder profiles and Board Members

InNeuroCo's employee count trend

InNeuroCo has 20 employees as of Apr 26. Here is InNeuroCo's employee count trend over the years:

Uncover InNeuroCo's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of InNeuroCo include Q’Apel Medical, Huake Precision (Beijing) Medical Technology and Brain Navi Biotechnology. Here is the list of Top 10 competitors of InNeuroCo, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Q’Apel Medical 2019, Fremont (United States), Series D	Provider of the medical device for the treatment of neurovascular interventions disorder	$51.9M	Soleus Capital, RC Capital & 1 others	49/100
2nd	Huake Precision (Beijing) Medical Technology 2003, Beijing (China), Series D	Provider of a neurosurgery robot for neurological treatments	$13.9M	China Growth Capital, Medtronic & 11 others	47/100
3rd	Brain Navi Biotechnology 2015, Zhubei (Taiwan), Funding Raised	Manufacturer of neurological robot for surgery	-	Sunsino Venture Group, Kyber Capital	45/100
4th	Robeauté 2017, Paris (France), Seed	Developer of microrobots for neurosurgical applications	$28M	Kindred Ventures, Cherry Ventures & 7 others	42/100
5th	Vycor Medical 2005, Boca Raton (United States), Public	Innovative neurosurgical and neurotherapeutic solutions improving lives through advanced medical devices	-	-	41/100
6th	Zeta Surgical 2016, Boston (United States), Seed	Developer of AI-based navigation and robotics system for surgeries	$8.16M	Innospark Ventures, MassChallenge & 9 others	41/100
7th	InNeuroCo 2014, Sunrise (United States), Acquired	Intermediate catheters and super distal access device for neurovascular surgery	$1.51M	-	37/100
8th	ClaroNav 2001, Toronto (Canada), Series B	Developer of medical 3D visualization and surgical navigation solutions	$1.52M	BDC	38/100
9th	inTRAvent Medical 2015, Hershey (United States), Unfunded	Developer of intraoperative imaging and navigation system for neurosurgical procedures	-	-	37/100
10th	Medsurant Monitoring 2011, Denver (United States), Public	Premier neurodiagnostics provider offering compassionate patient care and training programs	$10.2M	New Capital Partners, Volante	34/100